Corporate Symposia Schedule
Wednesday, May 1
11:30 am – 12:45 pm
Emapalumab – A New Treatment for Patients with Primary HLH (pHLH)
Michael B. Jordan, MD; Professor Franco Locatelli
This non-CME symposium will highlight the burden patients with pHLH experience as well as the clinical study data of the newly approved therapy emapalumab. The session format will be an open forum to ensure engagement. Leading physicians in the treatment of pHLH, will host the presentation and will be available to answer any questions that may arise during the session.
This non-CME symposium is supported by Sobi, Inc.
Thursday, May 2
HEMLIBRA: A New Approach to Prophylaxis in Hemophilia A
Guy Young, MD
This non-CME symposium panel discussion will cover HEMLIBRA clinical trial data, novel mechanism of action, dosing and administration, and prescribing information. Unique perspectives from patients/caregivers will be shared.
This non-CME symposium is supported by Genentech.
Friday, May 3
Sickle Cell Disease: The Impact of Chronic Anemia and Hemolysis and Emerging Therapeutic Options
Non-CME Breakfast Symposium - Exhibit Hall Education Theater
Sickle cell disease (SCD) is a debilitating hemoglobinopathy characterized by anemia, hemolysis and vaso-occlusion. Scientific literature suggests an association between anemia, hemolysis and end-organ damage. This symposium will discuss clinical manifestations of hemolytic anemia related to organ damage, highlight the importance of brain health and review emerging therapies targeting anemia and hemolysis.
- Understanding pathophysiologic processes involved in anemia and hemolysis-related end-organ damage in SCD
- Discuss the impact of anemia and hemolysis on brain health in pediatric patients with SCD, and the importance of screening, including neurocognitive testing and MRI imaging
- Evaluate existing treatments and emerging drug therapies for treating chronic anemia in SCD.
This non-CME symposium is supported by Global Blood Therapeutics.